D. Eidelberg et al., ASSESSMENT OF DISEASE SEVERITY IN PARKINSONISM WITH FLUORINE-18-FLUORODEOXYGLUCOSE AND PET, The Journal of nuclear medicine, 36(3), 1995, pp. 378-383
Fluorine-18-fluorodeoxyglucose (FDG) and PET have been used to identif
y an abnormal regional metabolic covariance pattern in Parkinson's dis
ease (PD). To examine the potential use of this covariance pattern as
a metabolic imaging marker for PD, we describe the Topographic Profile
Rating (TPR), which is a method for calculating subject scores for th
is pattern in individual PD patients. We then assess the relationship
between these metabolic measures and objective independent disease sev
erity ratings. Methods: Two independent groups of PD patients were stu
died with FDG-PET. Group A consisted of 23 patients (mean age 60.2 +/-
12.2; mean Hoehn and Yahr stages 2.4 +/- 1.3) and Group B had 14 pati
ents (mean age 49.0 +/- 12.1; mean Hoehn and Yahr stage 3.2 +/- 1.2).
The regional cerebral metabolic rates for glucose (rCMRGlc) in all pat
ients in each group were measured. TPR was used to calculate subject s
cores for the disease-related covariance pattern on a patient-by-patie
nt basis. Results: In both PD patient groups, subject scores correlate
d with Hoehn and Yahr disease severity ratings (Group A: r = 0.59, p <
0.004; Group B: 0.57, p < 0.04), quantitative ratings for bradykinesi
a (Group A: r = 0.63, p < 0.002; Group B: r = 0.61, p < 0.03), rigidit
y (Group A: r = 0.59, p < 0.004; Group B: r = 0.59, p < 0.04), but not
with tremor. Conclusion: These findings indicate that regional metabo
lic covariance patterns are robust imaging markers of disease severity
. FDG-PET may be useful clinically in assessing parkinsonian disabilit
y and disease progression.